Cargando…

Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate

OBJECTIVES: Real-world experience from a 6-month product familiarization programme (PFP) for 3-monthly paliperidone palmitate in schizophrenia maintenance treatment. METHODS: Prescribers completed an online questionnaire for each patient at enrolment with further questions at second dose (re-supply)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pai, Nagesh, Warden, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Pharmacotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282161/ https://www.ncbi.nlm.nih.gov/pubmed/30047801 http://dx.doi.org/10.1177/1039856218789770

Ejemplares similares

Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
por: Bell Lynum, Karimah S., et al.
Publicado: (2018)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews, Maju, et al.
Publicado: (2019)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
por: Kim, Shiyun, et al.
Publicado: (2012)

Testosterone Management in Aging Males: Surveying Clinical Practices of Urologists and Endocrinologists in Israel
por: Ishay, Avraham, et al.
Publicado: (2019)

New Zealand community mental healthcare provider experience in schizophrenia management with 3-monthly paliperidone palmitate
por: Cassidy, Cathal, et al.
Publicado: (2020)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez, Alicia, et al.
Publicado: (2019)

Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia
por: Turkoz, Ibrahim, et al.
Publicado: (2023)

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
por: Mathews, Maju, et al.
Publicado: (2018)

Differences of use between paliperidone palmitate 3 month and paliperidone palmitate 1 month in real practice, with psychotic patients
por: Escobedo-Aedo, P., et al.
Publicado: (2022)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Twelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma
por: Raphael, Gordon, et al.
Publicado: (2016)

Endothelial Dysfunction in Patients With Erectile Dysfunction: A Double-Blind, Randomized-Control Trial Using Tadalafil
por: Pattanaik, Smita, et al.
Publicado: (2019)

Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy
por: Cattaneo, Mattia, et al.
Publicado: (2019)

AF in Cancer Patients: A Different Need for Anticoagulation?
por: Sanz, Ana Pardo, et al.
Publicado: (2019)

Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?
por: Battistoni, Allegra, et al.
Publicado: (2020)

Safety and Tolerability of Evening Ethanol Consumption and Bedtime Administration of Flibanserin in Healthy Premenopausal Female Subjects
por: Millheiser, Leah, et al.
Publicado: (2019)

Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy
por: Camarero, Tamara García, et al.
Publicado: (2020)

Antithrombotic Therapy After Transcatheter Aortic Valve Implantation
por: Lugo, Leslie Marisol, et al.
Publicado: (2020)

Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?
por: Abdelnabi, Mahmoud, et al.
Publicado: (2020)

The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study
por: Gallo, Luigi, et al.
Publicado: (2020)

Effect of Icariside II and Metformin on Penile Erectile Function, Histological Structure, Mitochondrial Autophagy, Glucose-Lipid Metabolism, Angiotensin II and Sex Hormone in Type 2 Diabetic Rats With Erectile Dysfunction
por: Zhang, Jian, et al.
Publicado: (2020)

The Effect of Food on the Pharmacokinetics of Buspirone After Single Administration of a Sublingual Testosterone and Oral Buspirone Combination Tablet in Healthy Female Subjects
por: Gerritsen, Jeroen, et al.
Publicado: (2020)

A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
por: Ahmad, Tariq, et al.
Publicado: (2021)

D-53 | Impact of Cardiovascular Diseases, Calcium Channel Blockers and Beta-Blockers on Mortality of Patients Hospitalized with COVID-19
por: Alhusain, Rashid, et al.
Publicado: (2022)

Effect of the new 75-mg orodispersible film of sildenafil on erection and sexual quality of life: insights from an observational study
por: Sansone, Andrea, et al.
Publicado: (2023)

Efficacy and safety outcomes of a compounded testosterone pellet versus a branded testosterone pellet in men with testosterone deficiency: a single-center, open-label, randomized trial
por: Kresch, Eliyahu, et al.
Publicado: (2023)

STOMp: sexual function trial of overactive bladder medication
por: Polland, Allison, et al.
Publicado: (2023)

The availability of gonadotropin therapy from FDA-approved pharmacies for men with hypogonadism and infertility
por: Borgert, Benjamin J, et al.
Publicado: (2023)

Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients
por: Komiyama, Maki, et al.
Publicado: (2023)

Nuclear Factor-κB is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease
por: Matsumori, Akira
Publicado: (2023)

Carotid artery intima media thickness can predict the response to phosphodiesterase 5 inhibitors in patients with moderate erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)

Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel
por: Tan, Cheng Keat, et al.
Publicado: (2023)

Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis
por: Shin, Young Eun, et al.
Publicado: (2023)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash, Abigail I, et al.
Publicado: (2019)

Review of pharmacotherapy for smoking cessation in patients with schizophrenia
por: Shawen, Avery E., et al.
Publicado: (2018)

Clinical experiences with 6-monthly paliperidone palmitate beyond the diagnosis of schizophrenia. A retrospective study
por: Benavente López, S., et al.
Publicado: (2023)

Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
por: Corbeil, Olivier, et al.
Publicado: (2022)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury, Antoine C, et al.
Publicado: (2021)

Different onset patterns of monthly paliperidone palmitate in hospitalised patient diagnosed with schizophrenia
por: Herrera-Sánchez, Javier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fimqfl8kkebuijsh65g5ge17bo